Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.

Meningococcal septic shock has a rapid onset and characteristic skin hemorrhages that allow bedside diagnosis. Initial plasma endotoxin levels are high and correlate closely with clinical outcome. In a double-blind, randomized, placebo-controlled trial (planned, n = 270; actual, n = 269), we compared the effectiveness of HA-1A (6 mg/kg of body weight iv; maximum, 100 mg), a human monoclonal antibody to endotoxin, and placebo in reducing the 28-day all-cause mortality rate among children with a presumptive clinical diagnosis of meningococcal septic shock. Treatment groups were well balanced for baseline characteristics and prespecified prognostic variables. In this trial no significant benefit of HA-1A could be demonstrated. The 28-day mortality rates in the intention-to-treat analysis were as follows: placebo, 28%; HA-1A, 18%; reduction in mortality, 33% (P = .11, per Fisher's exact test, two-tailed; odds ratio = 0.59; 95% confidence interval for the difference, 0.31-1.05). All patients tolerated HA-1A well, and no antibodies to HA-1A were detected.

[1]  B. Giroir,et al.  Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. , 1996, The Pediatric infectious disease journal.

[2]  P. Brandtzaeg.  Systemic meningococcal disease: Clinical pictures and pathophysiological background , 1996 .

[3]  R. Sauerwein,et al.  Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. , 1995, The Journal of infectious diseases.

[4]  J. Sjölin,et al.  Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. , 1995, The Journal of infectious diseases.

[5]  S. Opal,et al.  Endotoxin's role in Gram-negative bacterial infection , 1995 .

[6]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[7]  R. Dellinger,et al.  Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain , 1993, Infection and immunity.

[8]  B. Lindner,et al.  Structural characterization of the lipid A component of pathogenic Neisseria meningitidis , 1992, Journal of bacteriology.

[9]  S. Suter,et al.  118 TREATMENT OF SEVERE INFECTIOUS PURPURA IN CHILDREN WILL HUMAN PLASMA FROM DONORS IMMUNIZED WITH ESCHERICHILA COLI JS: A PROSPECTIVE, DOUBLE BLIND STUDY , 1991, Pediatric Research.

[10]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[11]  A. Martinot,et al.  Prognostic value of C‐reactive protein level in severe infectious purpura: A comparison with eight other scores , 1991, Critical care medicine.

[12]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[13]  C. Hart,et al.  Validation of the Glasgow Meningococcal Septicemia Prognostic Score: A 10‐year retrospective survey , 1991, Critical care medicine.

[14]  P. Brandtzaeg,et al.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[15]  H. Kaplan,et al.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T R Fleming,et al.  Designs for group sequential tests. , 1984, Controlled clinical trials.

[17]  K. Tanaka,et al.  Characterization of specific binding of 3H-phorbol dibutyrate to Friend leukemia cells. , 1983, Gan.

[18]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[19]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[20]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .

[21]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[22]  E. Stiehm,et al.  Factors in the prognosis ofmeningococcal infection , 1966 .

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[25]  R. Heyderman,et al.  Assessment of the effect of candidate anti-inflammatory treatments on the interaction between meningococci and inflammatory cellsin vitro in a whole blood model , 1996, Biotherapy.

[26]  S. Suter,et al.  Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group. , 1992, The Journal of infectious diseases.

[27]  J. Christy,et al.  Treatment of gram-negative shock. , 1971, The American journal of medicine.

[28]  E. Stiehm,et al.  Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient. , 1966, The Journal of pediatrics.